Alkem Laboratories Ltd
ALKEMAlkem Laboratories Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: Promoters moved −6.7 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced.
The price is topping out (17 weeks in) while the P/E sits at the 44th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit −22.0% year on year, and 91% of the last 3 years' profit arrived as cash. What settles it: whether the register turns back in the story’s favour.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Alkem Laboratories Ltd trades at ₹5,563, losing momentum at the top and 17 weeks into that stage. That is +2.0% against its own 200-day average. It sits at 57% of a 52-week range of ₹5,204 to ₹5,837. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is losing momentum at the top — week 17 of stage 3, confirmed. At ₹5,563 it trades +2.0% versus its 200-day average and sits at 57% of its 52-week range (₹5,204–₹5,837).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +307% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-07-01) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 44th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Alkem Laboratories Ltd trades at 27.6× P/E, mid-range by its own standards (44th percentile). Its long-run median P/E is 28.3×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 27.6× is mid-range by its own standards (44th percentile), against a long-run median of 28.3× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +6.3% against a +11.3% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +10.7%/yr price move, ~+9.4%/yr came from earnings growth and ~+1.3 pp from the multiple (expanding); over 10y, of the +14.7%/yr price move, ~+12.0%/yr came from earnings growth and ~+2.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5.6% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Alkem Laboratories Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE lifting at 21.0% — the per-curve reads carry the story. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +13.5% | +8.2% | +10.7% | +11.6% |
| Profit | +6.1% | +32.7% | +7.8% | +12.1% |
| EPS | +6.3% | +32.7% | +7.7% | +12.0% |
| Share price | +11.3% | +16.5% | +10.7% | +14.7% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
53.8/100 — rank 18 of 43 in Pharma - Formulators · 79% evidence confidence
Alkem Laboratories Ltd scores 53.8 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 18. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 20.3 + 16.4 + 12.4 + 4.7 = 53.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Alkem Laboratories Ltd reported ₹3,603 Cr of revenue in the Mar 26 quarter, +14.6% year on year. That is the 6th straight quarter of year-on-year growth. Over 10 years it has compounded at 11.6% a year. The last full year, FY26, came in at ₹14,712 Cr. The last four reported quarters add to ₹14,712 Cr.
Alkem Laboratories Ltd reported ₹3,603 Cr of revenue in the Mar 26 quarter, +14.6% year on year. That is the 6th straight quarter of year-on-year growth. Over 10 years it has compounded at 11.6% a year. The last full year, FY26, came in at ₹14,712 Cr. The last four reported quarters add to ₹14,712 Cr.
FY26 revenue came in at ₹14,712 Cr (+13.5% on the year), capping 10 years at 11.6% compound. The latest quarter (Mar 26) printed ₹3,603 Cr, +14.6% year on year — the 6th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +13.5% growth against the decade's 11.6% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +13.5% over the last 4 quarters against +7.8%/yr over the last 8 — accelerating; TTM profit +6.1% vs +13.9%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 14.0% this quarter (+2.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Alkem Laboratories Ltd's operating margin is 14.0% in the Mar 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0% to 22.0%. The current quarter sits inside that band.
Alkem Laboratories Ltd's operating margin is 14.0% in the Mar 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0% to 22.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 14.0%, +2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0%–22.0%.
Why the margin moved: operating margin went +1.9 pp year on year while gross margin went +6.1 pp — the gain came mostly from the gross line: input costs and pricing.
→ Margins held — did that reach the bottom line? Next: profit −22.0% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Alkem Laboratories Ltd earned ₹251 Cr of net profit in the Mar 26 quarter, −22.0% year on year. Full-year FY26 profit was ₹2,351 Cr. The 10-year compound rate is 12.1%. That is 7.0% of the quarter's revenue. The same quarter a year earlier earned ₹322 Cr.
Alkem Laboratories Ltd earned ₹251 Cr of net profit in the Mar 26 quarter, −22.0% year on year. Full-year FY26 profit was ₹2,351 Cr. The 10-year compound rate is 12.1%. That is 7.0% of the quarter's revenue. The same quarter a year earlier earned ₹322 Cr.
Mar 26 profit was ₹251 Cr, −22.0% year on year. On the full year, FY26 printed ₹2,351 Cr (+6.1%), and the 10-year compound rate is 12.1%.
🚨 Why profit moved: revenue contributed +14.6% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +3.1% vs revenue +13.5%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 91% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 91% of Alkem Laboratories Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹1,963 Cr of operating cash against ₹2,351 Cr of profit. After ₹1,135 Cr of capital spending, ₹828 Cr was left as free cash.
FY26: operating cash of ₹1,963 Cr against reported profit of ₹2,351 Cr, leaving free cash of ₹828 Cr after ₹1,135 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 91% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 91%: the cash cycle tightened 44 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 2.1× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹2,185 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Alkem Laboratories Ltd's cash conversion cycle runs 152 days in FY26, down from 196 days in FY21. Capital spending ran ₹2,185 Cr over the last 3 years. At FY26 sales of ₹14,712 Cr each day of that cycle holds about ₹40.3 Cr, so roughly ₹6,127 Cr sits inside the business at any moment.
FY26: debtors at 74 days, inventory at 239 days — roughly 7.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 152 days, tighter than FY21's 196.
The full loop: cash goes out to suppliers and production on day 0; stock waits 239 days to sell; customers pay about 74 days after that; and suppliers themselves are paid at 161 days — netting out to the 152-day cycle.
In money terms: at FY26 sales of ₹14,712 Cr, each day of the cycle holds about ₹40.3 Cr — so the 152-day loop keeps roughly ₹6,127 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹2,185 Cr over the last 3 fiscal years against ₹1,038 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹138 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 21%.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Alkem Laboratories Ltd earns a ROCE of 21% in FY26. That is up from a trough of 12% in FY15. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 16.0% net margin on 0.70× asset turns.
FY26 ROCE is 21%, recovered from a FY15 trough of 12% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 16.0% net margin × 0.70× asset turns × 1.51× balance-sheet leverage ≈ 16.9% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5.6% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.15.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Alkem Laboratories Ltd carries ₹2,047 Cr of borrowings against ₹13,820 Cr of equity in FY26, a debt-to-equity of 0.15. Operating profit covers the interest bill 19×. Over 5 years borrowings went from ₹1,707 Cr to ₹2,047 Cr. Capital spending ran ₹2,185 Cr across the last 3 of those years.
FY26: borrowings of ₹2,047 Cr against equity of ₹13,820 Cr — a debt-to-equity of 0.15. Operating profit covers the interest bill 19×. Over 5 years borrowings went from ₹1,707 Cr to ₹2,047 Cr while capital spending ran ₹2,185 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5.6% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Who owns this, and are they adding or leaving? Next: Promoters cut 6.7 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 6.7 points of Alkem Laboratories Ltd over 8 quarters, the biggest move on the register. That takes promoters to 49.7% of the company. Domestic institutions moved +4.1 points over the same window, to 22.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −6.7 points over 8 quarters to 49.7%; Domestic institutions: +4.1 points over 8 quarters to 22.6%; Foreign institutions: +1.7 points over 8 quarters to 10.4%.
🚨 Why the register moved: promoters drove it (−6.7 points), absorbed on the other side by domestic institutions (+4.1 points) — distribution into the market’s bid.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Alkem Laboratories Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Alkem Laboratories Ltd this page | 27.6× | ₹67,357 Cr | Mixed | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Alkem Laboratories Ltd's share price today?
Alkem Laboratories Ltd trades at ₹5,563, +11.3% over the past year. The company is valued at ₹67,357 Cr. The stock sits at 57% of its 52-week range of ₹5,204–₹5,837, +2.0% versus its 200-day average. On the tape, the price is topping out, 17 weeks in. — as of 24 July 2026.
What were Alkem Laboratories Ltd's latest quarterly results?
Alkem Laboratories Ltd reported revenue of ₹3,603 Cr and net profit of ₹251 Cr for the Mar 26 quarter. Revenue rose 14.6% and profit fell 22.0% year on year. Earnings per share were ₹19.78. The operating margin was 14.0%, 2.0 pp higher than a year earlier. — as of 24 July 2026.
What is Alkem Laboratories Ltd's revenue?
Alkem Laboratories Ltd reported revenue of ₹3,603 Cr in the Mar 26 quarter, +14.6% year on year. For the full FY26 fiscal year, revenue was ₹14,712 Cr (+13.5%). Over the last 10 years revenue compounded at 11.6% a year. — as of 24 July 2026.
What is Alkem Laboratories Ltd's profit?
Alkem Laboratories Ltd earned ₹251 Cr of net profit in the Mar 26 quarter, −22.0% year on year. Full-year FY26 profit was ₹2,351 Cr. The operating margin ran 14.0% in the latest quarter. — as of 24 July 2026.
What is Alkem Laboratories Ltd's market cap?
Alkem Laboratories Ltd's market capitalisation is ₹67,357 Cr at a share price of ₹5,563. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Alkem Laboratories Ltd's P/E ratio?
Alkem Laboratories Ltd trades at a P/E of 27.6×, at the 44th percentile of its own 10-year range, against a long-run median of 28.3×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Alkem Laboratories Ltd pay a dividend?
Yes — Alkem Laboratories Ltd's dividend payout was 28% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Alkem Laboratories Ltd overvalued?
On its own history, Alkem Laboratories Ltd looks mid-range against its own history: its P/E of 27.6× sits at the 44th percentile of its 10-year range (long-run median 28.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Alkem Laboratories Ltd growing?
Yes — Alkem Laboratories Ltd is growing: latest-quarter revenue +14.6% year on year, profit −22.0%, and the margin +2.0 pp at 14.0%. The 10-year compound rates are 11.6% (revenue) and 12.1% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Alkem Laboratories Ltd performing?
Alkem Laboratories Ltd is topping out, 17 weeks in. Its latest quarter's revenue rose 14.6% and profit fell 22.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Alkem Laboratories Ltd in?
Mixed — no clean majority across the growth curves, ROCE lifting at 21.0% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +14.6% latest, profit growth −22.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Alkem Laboratories Ltd in an uptrend?
It is stalling — the price is topping out (week 17 of stage 3), trading +2.0% versus its 200-day average and at 57% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Alkem Laboratories Ltd beating the market?
Not lately — on a trailing-13-week view Alkem Laboratories Ltd is currently behind the NIFTY 500 (3 weeks and counting; last ahead the week of 2026-07-01), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved +307% against the NIFTY 500's +274% — ahead of the index over the full window. — as of 24 July 2026.
Will Alkem Laboratories Ltd's share price go up?
This page publishes no price forecast for Alkem Laboratories Ltd. What it measures instead: the share price is ₹5,563, the price is topping out 17 weeks in. Its P/E of 27.6× sits at the 44th percentile of its own 10-year range. Direction is not something this site claims to know. — as of 24 July 2026.
Who owns Alkem Laboratories Ltd?
Promoters hold 49.7% of Alkem Laboratories Ltd, foreign institutions 10.4%, domestic institutions 22.6% and the public 17.3% (latest quarter). The biggest move on the register over the last two years: Promoters cut 6.7 points over 8 quarters. — as of 24 July 2026.
Does Alkem Laboratories Ltd have too much debt?
No — Alkem Laboratories Ltd's debt-to-equity is 0.15, and operating profit covers the interest bill 19×. FY26 borrowings were ₹2,047 Cr against equity of ₹13,820 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Alkem Laboratories Ltd's capex?
Alkem Laboratories Ltd spent ₹2,185 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹1,135 Cr, with ₹138 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Alkem Laboratories Ltd's cash flow?
Alkem Laboratories Ltd generated ₹1,963 Cr of operating cash flow in FY26 and ₹828 Cr of free cash flow after ₹1,135 Cr of capital spending. Reported profit that year was ₹2,351 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Alkem Laboratories Ltd's profit real cash?
Yes — over the last 3 fiscal years, 91% of Alkem Laboratories Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹1,963 Cr against reported profit of ₹2,351 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Alkem Laboratories Ltd in its business cycle?
Alkem Laboratories Ltd's FY26 operating margin was 20.0%, against a 13-year band of 12.0%–22.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 14.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Alkem Laboratories Ltd story?
The sharpest disagreement: Promoters moved −6.7 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Alkem Laboratories Ltd a stock worth studying right now?
This is not investment advice. The machine read: Alkem Laboratories Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the register turns back in the story’s favour. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.